OSI-774 (Tarceva) Plus Gemcitabine in Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer.
Status:
Completed
Trial end date:
2004-01-15
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if OSI-774 will improve overall survival when
combined with a standard dose of the chemotherapy drug gemcitabine, to individuals with
pancreatic cancer.
Phase:
Phase 3
Details
Lead Sponsor:
OSI Pharmaceuticals
Collaborators:
Canadian Cancer Trials Group NCIC Clinical Trials Group